Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis

doi:10.3748/wjg.v11.i26.4067

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 26

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4562)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-7) series.

Item

Count

PDF

344

HTML

3845

Figures (1-3)

181

Tables (1-7)

192

Sum=4562

Jul 14, 2005 (publication date) through Nov 9, 2024

Times Cited of This Article

Times Cited (57)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Jul 14, 2005; 11(26): 4067-4077
Published online Jul 14, 2005. doi: 10.3748/wjg.v11.i26.4067

Table 1 Healing rate of esophagitis by ITT with standard dose vs high dose of H₂RA at 3, 4, 6, 8, 12 wk

		3-wk	4-wk	6-wk	8-wk	12-wk
Number of comparisons		1	5	9	5	12
High dose	Pooled data	29/169	297/669	607/1 294	413/669	1 142/1 729
	Pooled healing rate (%)	17.2	44.4	46.9	61.7	66.0
Standard dose	Pooled data	33/168	198/573	584/1 361	309/573	920/1 520
	Pooled healing rate (%)	19.6	34.6	42.9	53.9	60.5
Summary RR		0.874	1.281	1.096	1.165	1.084
95% CI		0.557-1.371	1.036-1.583	0.930-1.293	1.020-1.329	1.019-1.152

ITT, intention-to-treat analysis; No, number; RR, relative risk; 95%CI.

Table 2 Healing rate of esophagitis by ITT at 2, 3, 4, 8, 12 wk comparing proton pump inhibitors (PPIs) with H₂RA

	PPIs				H₂RA
	2-wk	4-wk	8-wk	12-wk	2-wk	4-wk	8-wk	12-wk
sd PPIs vs sd H₂RA
Number of arms	2	13	12		2	13	12
Pooled data	116/183	577/824	640/783		60/163	271/713	350/673
Pooled healing rate (%)	63.4	70.0	81.7		36.8	38.0	52.0
Summary RR	1.759	1.832	1.586
95%CI	1.398-2.213	1.622-2.070	1.438-1.749
hd PPIs vs sd H₂RA
Number of arms		4	4	1		4	4	1
Pooled data		150/204	175/201	72/80		79/211	106/207	49/81
Pooled healing rate (%)		73.5	87.1	90.0		37.4	51.2	60.5
Summary RR		1.722	1.623	1.488
95%CI		1.464-2.027	1.417-1.859	1.230-1.800
sd PPIs vs hd H₂RA
Number of arms		2	2		2	2
Pooled data		152/235	208/235		87/234	155/234
Pooled healing rate (%)		64.7	88.5		37.2	66.2
Summary RR		1.744	1.336
95%CI		1.442-2.110	1.206-1.481
ld PPIs vs sd H₂RA
Number of arms		3	3		3	3
Pooled data		187/279	219/279		120/276	161/276
Pooled healing rate (%)		67.0	78.5		43.5	58.3
Summary RR		1.605	1.374
95%CI		1.156-2.229	1.081-1.744

hd: high dose; sd: standard dose; ld: low dose; ITT, intention-to-treat analysis; No., number; RR, relative risk; 95% CI, 95% CIs.

Table 3 Healing rate (ITT) of esophagitis at 2, 4, 8 wk comparing PPIs with omeprazole

	Other PPIs			Omeprazole
	2-wk	4-wk	8-wk	2-wk	4-wk	8-wk
sd PPIs vs sd Omeprazole
Number of arms	1	12	12	1	12	12
Pooled data	264/421	2 615/3 412	3 050/3 411	257/431	2 229/3 217	2 719/3 216
Pooled healing rate (%)	62.7	76.6	89.4	59.6	69.3	84.5
Summary RR				1.052	1.044	1.061
95%CI				0.945–1.171	0.983-1.109	0.979-1.055
ld PPIs vs sd Omeprazole
Number of arms		2	2		2	2
Pooled data		590/822	724/822		551/811	707/811
Pooled healing rate (%)		71.8	88.1		67.9	87.2
Summary RR					1.026 0.981
95%CI					0.904-1.164	0.870-1.105
sd PPIs vs hd Omeprazole
Number of arms		2	1		2	1
Pooled data		310/440	284/337		302/434	282/332
Pooled healing rate (%)		70.5	84.3		69.6	84.9
Summary RR					1.031	0.985
95%CI					0.937-1.015	0.883-1.099

hd: high dose; sd: standard dose; ld: low dose; ITT, intention-to-treat analysis; No., number; RR, relative risk; 95% CI, 95% CIs.

Table 4 Healing rate of refractory esophagitis at 2, 4, 6, 8, 12 wk comparing PPIs with H₂RA

Author	PPIs						H₂RAs
	Number of			Healing rate ( ITT )			Number of			Healing rate ( ITT )
	Drug	Dose	Patient	4 wk	8 wk	12 wk	Drug	Dose	Patient	4 wk	8 wk	12 wk
sd PPIs vs sd H₂RA
Feldman ⁽⁵⁵⁾	Lan	30 o.d.	61		54/61		Ran	150 b.d.	32		12/32
Sontag ⁽⁵⁶⁾	Lan	30 o.d.	105	75/105	84/105		Ran	150 b.d.	54	28/54	16/54¹
Pooled data			166	75/105	138/166				86	28/54	28/86
Pooled rate (%)				71.4	83.1					51.9	32.6
hd PPIs vs hd H₂RA
Lundell ⁽⁵⁷⁾	Ome	40 o.d.	51	32/51	35/51	46/51	Ran	300 b.d.	47	8/47	18/47	22/47

Ome: omeprazole; Lan: lansoprazole; Ran: ranitidine; o.d.: once daily in the morning; b.d.: twice daily; h.d.: high dose; sd: standard dose. This study did not report cumulative healing rate at 8 wk. All patients’ endpoint was at 8 wk. The decreased healing rate at 8 wk for ranitidine group may be due to subsequent relapse of esophagitis.

Table 5 Healing by grade with standard dose vs high dose of H₂RA at 4, 6, 8, 12 wk (PP rate)

		4-wk		6-wk			8-wk		12-wk
		II	III	I	II	III	II	III	I	II	III
Number of arms		3	3	4	4	4	3	3	4	6	6
Standard dose	Pooled data	84/190	22/105	86/137	102/266	42/180	126/187	37/105	107/129	264/383	119/256
	Pooled rate (%)	44.2	21.0	62.8	38.3	23.3	67.4	35.2	82.9	69.0	46.5
High dose	Pooled data	177/325	60/198	112/157	120/272	60/214	226/323	92/198	122/153	400/532	190/376
	Pooled rate (%)	54.4	30.3	71.3	44.1	28.0	70.0	46.5	79.7	75.2	50.5
Summary RR
95% CI		1.231	1.430	1.136	1.150	1.200	1.039	1.316	0.962	1.032	1.059
		1.020-1.486	0.941-2.202	0.966-1.337	0.939-1.408	0.854-1.686	0.919-1.174	0.977-1.774	0.860-1.076	0.961-1.108	0.913-1.229

PP, per-protocol analysis; No., number; RR, relative risk; 95%CI.

Table 6 Healing by grade at 4, 8, 12 wk comparing PPIs with H₂RAs (PP rate)

		4 wk				8 wk				12 wk
		I	II	III	IV	I	II	III	IV	I	II
Number of arms		2	4	3		2	5	3	1
sd PPIs	Pooled data	53/60	128/162	20/54		23/23	166/178	28/47	2/3
	Pooled rate (%)	88.3	79.0	37.0		100.0	93.3	59.6	66.7
sd H₂RAs	Pooled data	27/54	65/172	2/41		16/25	101/182	6/34	0/2
	Pooled rate (%)	50.0	37.8	4.9		64.0	55.5	17.6	0
Summary RR		1.760	2.037	5.588		1.502	1.648	2.766	2.525
95%CI		1.329-2.332	1.631-2.545	1.701-18.363		1.107-2.038	1.440-1.885	1.284-5.916	1.046-6.093
No. of arms		2	4	2		2	4	2		1	1
hd PPIs	Pooled data	40/46	88/123	21/30		46/46	104/120	24/30		29/29	42/46
	Pooled rate (%)	87.0	71.5	70.0		100.0	86.7	80.0		100.0	91.3
sd H₂RAs	Pooled data	26/50	49/126	3/28		37/49	62/121	6/28		28/32	19/35
	Pooled rate (%)	52.0	38.9	10.7		75.5	51.2	21.4		87.5	54.3
Summary RR		1.665	1.835	6.110		1.300	1.689	3.626		1.111	1.676
95%CI		1.248-2.222	1.436-2.345	2.138-17.459		1.102-1.534	1.400-2.036	1.772-7.418		0.957-1.291	1.222-2.298
Number of arms		2	1	1		2	1	1
ld PPIs	Pooled data	144/175	34/42	9/28		162/175	42/44	15/28
	Pooled rate (%)	82.3	81.0	32.1		92.6	95.5	53.6
sd H₂RAs	Pooled data	104/175	15/50	1/22		132/175	27/49	2/21
	Pooled rate (%)	59.4	30.0	4.5		75.4	55.1	9.5
Summary RR		1.384	2.698	7.071		1.227	1.732	5.625
95%CI		1.202-1.592	1.724-4.224	0.967-51.707		1.116-1.349	1.335-2.249	1.440-21.980
Refractory esophagitis
Number of arms			1		1		2	1	2
sd PPIs	Pooled data		62/77		11/22		105/116	13/15	18/29
	Pooled rate (%)		80.5		50.0		90.5	86.7	62.1
sd H₂RAs	Pooled data		20/40		1/11		26/61	2/8	0/14
	Pooled rate (%)		50.0		9.1		42.6	25.0	0
Summary RR			1.606		5.500		2.117	3.229	35.881
95%CI			1.158-2.228		0.835-25.337		1.575-2.845	1.034-10.091	0.728-1767.6

sd: standard dose; ld: low dose.

Table 7 Healing by grade at 4, 8 wk comparing standard dose of other PPIs vs omeprazole

		4-wk				8-wk
		I	II	III	IV	I	II	III	IV
Number of arms		3	3	3	1	3	3	3	1
sd PPIs	Pooled data	195/239	302/362	148/210	3/7	214/235	329/360	175/209	2/4
	Pooled rate (%)	81.6	83.4	70.5	42.9	91.1	91.4	83.7	50.0
sd omeprazole	Pooled data	190/238	315/393	132/195	3/5	214/233	345/390	159/188	1/2
	Pooled rate (%)	79.8	80.2	67.8	60.0	91.8	88.5	84.6	50.0
Summary RR		1.022	1.041	1.041	0.733	0.992	1.033	0.990	1.000
95%CI		0.936-1.116	0.973-1.113	0.914-1.186	0.250-2.147	0.938-1.048	0.985-1.084	0.927-1.057	0.213-4.694

sd: standard dose.

Citation: Wang WH, Huang JQ, Zheng GF, Xia HHX, Wong WM, Lam SK, Wong BCY. Head-to-head comparison of H₂-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis. World J Gastroenterol 2005; 11(26): 4067-4077
URL: https://www.wjgnet.com/1007-9327/full/v11/i26/4067.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i26.4067